| Title |
Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
|
|---|---|
| Published in |
Cardiovascular Drugs and Therapy, June 2008
|
| DOI | 10.1007/s10557-008-6113-z |
| Pubmed ID | |
| Authors |
Fergus McTaggart, Peter Jones |
| Abstract |
The objective was to systematically review clinical trial data on the effects of statins on high-density lipoproteins (HDL) and to examine the possibility that this provides cardiovascular benefits in addition to those derived from reductions in low-density lipoproteins (LDL). |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| United Kingdom | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 163 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| China | 1 | <1% |
| Unknown | 162 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 23 | 14% |
| Student > Master | 19 | 12% |
| Student > Bachelor | 19 | 12% |
| Researcher | 14 | 9% |
| Student > Postgraduate | 13 | 8% |
| Other | 31 | 19% |
| Unknown | 44 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 43 | 26% |
| Agricultural and Biological Sciences | 20 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 8% |
| Biochemistry, Genetics and Molecular Biology | 8 | 5% |
| Unspecified | 5 | 3% |
| Other | 20 | 12% |
| Unknown | 54 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2023.
All research outputs
#2,225,097
of 23,884,161 outputs
Outputs from Cardiovascular Drugs and Therapy
#40
of 732 outputs
Outputs of similar age
#5,980
of 84,162 outputs
Outputs of similar age from Cardiovascular Drugs and Therapy
#1
of 2 outputs
Altmetric has tracked 23,884,161 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 732 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 84,162 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them